Oncor (United States)

Recent papers from Oncor (United States)

1. Reliable Execution of Consequential AI Agent Actions Under Retries and Ambiguous Outcomes2026
2. Occupation and oncology: cancer care in PalestineFrontiers in Oncology · 2026
3. Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER ProgramCancer Research and Treatment · 2026
4. Designer ⁶⁴ Cu Porphyrin–Trastuzumab Conjugates for Imaging of HER2-Positive Breast CancerChemical & Biomedical Imaging · 2026
5. Abstract 3021: ONM-421, a pH-responsive polymer-drug conjugate nanoparticle, delivers MMAE to solid tumors and shows antigen-independent antitumor efficacy in miceCancer Research · 2026
6. Abstract 3026: A polymer-drug conjugate platform for tumor specific drug delivery: Advancement of a clinically validated ultra pH-sensitive micelle technologyCancer Research · 2026
7. Preferential Formation and Stability of Copper Porphyrins amidst Other Metals in Dilute Aqueous Solution─Applications for RadiopharmaceuticalsInorganic Chemistry · 2026
8. The Gordie Howe International Bridge – Superstructure construction engineering: design and controlReport · 2025
9. Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunityThe Journal of Immunology · 2025
10. Papillary Tumor of Pineal Region; A Case ReportMiddle Eastern Cancer and Oncology Journal · 2025
11. Simulating left atrial arrhythmias with an interactive N-body modelJournal of Electrocardiology · 2024
12. Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expressionMolecular Therapy — Oncolytics · 2023
13. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancerNature Communications · 2022
14. Massively Digitized Power Grid: Opportunities and Challenges of Use-Inspired AIProceedings of the IEEE · 2022
15. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer2021
16. Epitranscriptomic addition of m 6 A regulates HIV-1 RNA stability and alternative splicing2021
17. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor ImmunityCancer Immunology Research · 2020
18. Oncolytic HSV Vectors and Anti-Tumor ImmunityCurrent Issues in Molecular Biology · 2020
19. Antibody interference by a non-neutralizing antibody abrogates humoral protection against Plasmodium liver stage2020
20. Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved TolerabilityMolecular Therapy — Oncolytics · 2020